There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Agios Pharma (NASDAQ:AGIO), BeiGene Ltd (NASDAQ:BGNE) and Exact Sciences (NASDAQ:EXAS) with bullish sentiments.
Agios Pharma (AGIO)
In a report released today, Chad Messer from Needham reiterated a Buy rating on Agios Pharma, with a price target of $89. The company’s shares opened today at $88.79.
According to TipRanks.com, Messer is a 4-star analyst with an average return of 12.1% and a 45.3% success rate. Messer covers the Healthcare sector, focusing on stocks such as Aerpio Pharmaceuticals Inc, Tracon Pharmaceutical, and Sarepta Therapeutics.
Agios Pharma has an analyst consensus of Strong Buy, with a price target consensus of $104.14, which is a 17.3% upside from current levels. In a report issued on July 20, SunTrust Robinson also reiterated a Buy rating on the stock with a $123 price target.
.
See today’s analyst top recommended stocks >>
BeiGene Ltd (BGNE)
Maxim Group analyst Jason McCarthy initiated coverage with a Buy rating on BeiGene Ltd today and set a price target of $225. The company’s shares opened today at $178.59.
McCarthy said:
“BeiGene announced the pricing of its Hong Kong initial public offering of 65,600,000 ordinary shares. Based on the assumed exchange rate, the public offering, priced at $13.76 (HK$108) per share or $178.9 per American Depositary Share (ADS) is expected to raise ~$903M (HK$7.08bn).”
According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 11.0% and a 43.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BeiGene Ltd with a $212.50 average price target, a 19.0% upside from current levels. In a report issued on July 23, Piper Jaffray also reiterated a Buy rating on the stock with a $200 price target.
.
Exact Sciences (EXAS)
In a report released today, Derik De Bruin from Merrill Lynch maintained a Buy rating on Exact Sciences, with a price target of $68. The company’s shares opened today at $48.26.
According to TipRanks.com, Bruin is a 3-star analyst with an average return of 2.6% and a 55.7% success rate. Bruin covers the Healthcare sector, focusing on stocks such as Myriad Genetics, Danaher Corp, and Waters Corp.
Exact Sciences has an analyst consensus of Strong Buy, with a price target consensus of $68.71, which is a 42.4% upside from current levels. In a report issued on July 19, Leerink Partners also maintained a Buy rating on the stock with a $76 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
